Capsigen Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 3

Capsigen General Information

Description

Operator of a biotechnology firm intended to engineer novel adeno-associated virus capsids to address difficult-to-treat diseases. The company's proprietary transcription-dependent directed evolution technology eliminates background noise and identifies fully functional capsids designed to meet complex disease-specific transduction profiles, enabling researchers and scientists to test large-scale libraries and determine, based on a specific set of criteria for the delivery and treatment of the disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1010 Washington Street
  • Suite 220
  • Vancouver, WA 98660
  • United States
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Drug Discovery
Corporate Office
  • 1010 Washington Street
  • Suite 220
  • Vancouver, WA 98660
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Capsigen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 01-Jan-2023 Completed Generating Revenue
2. Seed Round 01-Dec-2020 Completed Generating Revenue
1. University Spin-Out 01-Dec-2020 Completed Generating Revenue
To view Capsigen’s complete valuation and funding history, request access »

Capsigen Patents

Capsigen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260306661-A1 Capsids and methods of targeting neurons Pending 01-May-2023
AU-2024266671-A1 Capsids and methods of targeting nuerons Pending 01-May-2023
EP-4705490-A1 Capsids and methods of targeting nuerons Pending 01-May-2023
US-20250206783-A1 Transcription-dependent directed evolution of aav capsids having enhanced tropism Inactive 21-Mar-2022
WO-2023183304-A2 Transcription-dependent directed evolution of aav capsids having enhanced tropism Inactive 21-Mar-2022 C07K14/005
To view Capsigen’s complete patent history, request access »

Capsigen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Capsigen Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Creative Destruction Lab Accelerator/Incubator
MP Healthcare Venture Management Corporate Venture Capital Minority
OHSU University
To view Capsigen’s complete investors history, request access »

Capsigen FAQs

  • When was Capsigen founded?

    Capsigen was founded in 2020.

  • Where is Capsigen headquartered?

    Capsigen is headquartered in Vancouver, WA.

  • What is the size of Capsigen?

    Capsigen has 16 total employees.

  • What industry is Capsigen in?

    Capsigen’s primary industry is Biotechnology.

  • Is Capsigen a private or public company?

    Capsigen is a Private company.

  • What is Capsigen’s current revenue?

    The current revenue for Capsigen is .

  • Who are Capsigen’s investors?

    Creative Destruction Lab, MP Healthcare Venture Management, and OHSU have invested in Capsigen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process